Nanoparticle contrast agents for earlier breast cancer detection
Nanoparticle contrast agents for earlier breast cancer detection
批准号:
10392420
负责人:
David Peter Cormode
金额:
$43.94万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2024-04-30
关键词:
AddressAffectBehaviorBiologicalBloodBlood CirculationBody Weights and MeasuresBreastBreast Cancer DetectionBreast Cancer Early DetectionBreast Cancer ModelBreast Cancer Risk FactorBreast Cancer TreatmentCaliberClaustrophobiasClinicalClinical ChemistryClinical DataContrast MediaDataDetectionDigital MammographyDiseaseDrug KineticsEarly DiagnosisEffectivenessElementsEncapsulatedEquipmentExcretory functionFormulationGoldHigh Risk WomanHistologyHourHypersensitivityImageIn VitroInductively Coupled Plasma Mass SpectrometryIodineKidneyKidney FailureLibrariesMagnetic Resonance ImagingMalignant NeoplasmsMammographic screeningMammographyMethodsMinorNanosphereNanostructuresOrganPatientsPolymersPopulationProceduresPropertyPublishingRoentgen RaysSafetyScanningScreening procedureSilverSolubilitySpecificityStructureSystemTechniquesTestingTimeToxic effectTransgenic ModelTranslationsVariantWomananti-cancerbasebiodegradable polymerbiomaterial compatibilitycancer imagingcancer typecomparativecontrast enhancedcostcost effectivedesignflexibilityhigh riskhigh risk populationhydrophilicityimaging potentialimprovedin vitro Assayin vivomalignant breast neoplasmmortalitynanocrystalnanomaterialsnanoparticlenovelpolyphosphazenepreventpublic health relevancescreeningscreening programsilver sulfidesmall moleculetooltumor
中文摘要
项目摘要
乳腺癌是迄今为止最常见的癌症类型,也是女性第二大致命癌症。
乳腺癌早期检测的乳房X线摄影筛查计划很普遍。乳腺摄影
筛查降低了乳腺癌的死亡率,具有成本效益。然而,已经出现的情况是,
乳房X光检查对乳腺致密的女性(约10%的女性)不是很有效,灵敏度为30-
百分之六十此外,独立于较低的肿瘤检出率,乳腺致密的女性在
患乳腺癌的风险更高。因此,为了降低这一人群中乳腺癌的死亡率,
需要筛选技术。
双能量乳房X线摄影术最近已成为一种高度敏感和特异性的技术,
检测高密度乳腺妇女的癌症。一种用于双能量乳房X线摄影的造影剂,
识别肿瘤对乳腺致密的女性以及选定的高风险乳腺癌患者非常有益。
人口。目前可用的碘基造影剂具有差的药代动力学、低的肿瘤体积、低的肿瘤体积和低的肿瘤体积。
在许多患者中是禁忌的。而其他技术,如对比度增强
MRI可用于筛查乳腺致密的女性,但高成本和实际障碍阻碍了MRI的应用。
使用这些技术。
我们在此提出开发新型的、可生物降解的基于银的纳米颗粒(SBNP),以允许安全检测
乳腺癌风险较高的患者的肿瘤。我们发现银是一种能产生
双能量乳腺X射线摄影的出色对比度是一种新的乳腺X射线摄影变体,
在不同的X射线能量下获得。我们已经找到了使纳米颗粒稳定的方法,
生物相容性。我们选择了一种相对简单但灵活的纳米颗粒设计,以改善
翻译的可能性。纳米粒子应该很快在肿瘤中积累,使它们
在乳房X光检查中很明显,然后逐渐分解为肾脏排泄的成分。这
该提案解决了在癌症中使用纳米颗粒的关键挑战:排泄。作为这项提议的一部分,
我们将开发一种可生物降解的载体系统,可以将小的、高度亲水的纳米颗粒输送到
肿瘤,在分解和肾排泄之前。这种载体系统可能会产生广泛的影响,因为它可以
可以应用于许多不同的纳米颗粒类型和抗癌方法。
英文摘要
PROJECT SUMMARY
Breast cancer is by far the most common type of cancer and is the second most deadly cancer in women.
Breast cancer mammography screening programs for early detection are widespread. Mammography
screening reduces mortality from breast cancer and is cost-effective. However, it has emerged that
mammography is not very effective in women with dense breasts (about 10% of women), with sensitivity of 30-
60%. Moreover, independent of the lower chance of tumor detection, women with dense breasts are at a
higher risk of breast cancer. Therefore to reduce mortality from breast cancer in this population, better
screening techniques are needed.
Dual-energy mammography has recently emerged as a technique that is highly sensitive and specific for
detecting cancer in women with dense breasts. A contrast agent for dual-energy mammography that can
identify tumors would be highly beneficial in women with dense breasts, as well as in selected high-risk
populations. Currently available iodine-based contrast agents have poor pharmacokinetics, low tumor
accumulation and are contraindicated in many patients. While other techniques such as contrast-enhanced
MRI can be used for screening women with dense breasts, the high costs and practical obstacles prevent the
use of those techniques.
We herein propose to develop novel, biodegradable silver-based nanoparticles (SBNP) to allow safe detection
of tumors in patients at higher risk of breast cancer. We have found that silver is an element that produces
excellent contrast in dual-energy mammography a new variation of mammography where two images are
acquired at different x-ray energies. We have found methods that make the nanoparticles stable and
biocompatible. We have chosen a comparatively simple, yet flexible nanoparticle design in order to improve
the likelihood of translation. The nanoparticles should quickly accumulate in tumors, rendering them
conspicuous on mammography, before gradually breaking down into their components for renal excretion. This
proposal addresses a key challenge in the use of nanoparticles in cancer: excretion. As part of this proposal
we will develop a biodegradable carrier system that can deliver small, highly hydrophilic nanoparticles to
tumors, before breakdown and renal excretion. This carrier system could have a broad impact, since it could
be applied to numerous different nanoparticle types and anti-cancer approaches.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1021/acsami.2c06190
发表时间:
2022-08-03
期刊:
ACS APPLIED MATERIALS & INTERFACES
影响因子:
9.5
作者:
[Nieves, Lenitza M., Dong, Yuxi C., Rosario-Berrios, Derick N., Mossburg, Katherine, Hsu, Jessica C., Cramer, Gwendolyn M., Busch, Theresa M., Maidment, Andrew D. A., Cormode, David P.]
通讯作者:
Cormode, David P.
Silver chalcogenide nanoparticles: a review of their biomedical applications.
银樱桃剂纳米颗粒:对其生物医学应用的综述。
DOI:
10.1039/d0nr03872e
发表时间:
2021-12-02
期刊:
Nanoscale
影响因子:
6.7
作者:
[Nieves LM, Mossburg K, Hsu JC, Maidment ADA, Cormode DP]
通讯作者:
Cormode DP
DOI:
10.1021/acsami.1c18941
发表时间:
2021-12-15
期刊:
ACS applied materials & interfaces
影响因子:
9.5
作者:
[Hsu JC, Du Y, Sengupta A, Dong YC, Mossburg KJ, Bouché M, Maidment ADA, Weljie AM, Cormode DP]
通讯作者:
Cormode DP
DOI:
10.1039/d0nr05489e
发表时间:
2021-01-08
期刊:
Nanoscale
影响因子:
6.7
作者:
[Nieves LM , Hsu JC , Lau KC , Maidment ADA , Cormode DP ]
通讯作者:
Cormode DP
Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography
-
批准号:10459234
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2021
-
负责人:David Peter Cormode
-
依托单位:
Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma
-
批准号:10397989
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2021
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:9925060
-
项目类别:
-
资助金额:$52.44万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:9815637
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable gold nanoparticles as contrast agents for CT
-
批准号:9341531
-
项目类别:
-
资助金额:$22.3万
-
财政年份:2017
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging
-
批准号:9899293
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging
-
批准号:9242691
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:David Peter Cormode
-
依托单位:
Macrophage COX-2 as a target in breast cancer chemoprevention
-
批准号:8703435
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2014
-
负责人:David Peter Cormode
-
依托单位:
Macrophage COX-2 as a target in breast cancer chemoprevention
-
批准号:8842600
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2014
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8490376
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8678912
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:7952549
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8120348
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8474382
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
海外基金